Fosun International wins five awards at Asian Excellence Awards
Fosun International Limited and its Co-CEOs won five awards at the 16th Asian Excellence Awards, recognizing leadership and ESG performance. The company achieved an AAA MSCI ESG rating and set targets to reduce GHG emission intensity by 20% by 2034. Innovations in healthcare, including the HANSIZHUANG drug, and social initiatives like the Rural Doctors Program were also highlighted.
*this image is generated using AI for illustrative purposes only.
Fosun International Limited and its Co-CEOs, Chen Qiyu and Xu Xiaoliang, secured five accolades at the 16th Asian Excellence Award presented by Corporate Governance Asia on June 30, 2026. The Group received the Sustainable Asia Award 2026, Best Environmental Responsibility Award, and Best Corporate Communications Award, while both executives were honored as Asia's Best CEO. These awards recognize the company's operational resilience, ESG performance, and leadership in navigating a complex global business environment in 2025.
Corporate Governance Asia recognized Fosun for maintaining a strong strategic focus on core businesses and advancing the deep integration of ESG into its operations. The organization highlighted the company's progress in green development, biodiversity conservation, and public health. Other award recipients included Sino Land, Sun Hung Kai Properties, Bank of China (Hong Kong), and PetroChina.
ESG Ratings and Climate Targets
Fosun International reported significant upgrades in its sustainability ratings during 2025. The MSCI ESG rating was upgraded to AAA, the highest level, while the Hang Seng Sustainability Rating was maintained at AA-. The company was included in S&P Global's Sustainability Yearbook 2026, ranking among the top 1% in China. Additionally, the FTSE Russell ESG score rose to 4.2, and the company was included in the FTSE4Good Index Series for the fifth consecutive time.
| Rating Agency | Rating/Score | Status |
|---|---|---|
| MSCI ESG | AAA | Upgraded to highest level |
| Hang Seng Sustainability | AA- | Maintained |
| FTSE Russell ESG | 4.2 | Included in FTSE4Good Index Series |
| S&P Global | Top 1% in China | Included in Sustainability Yearbook 2026 |
Regarding climate action, Fosun has committed to peaking carbon emissions by 2028 and achieving carbon neutrality by 2050. The Group has set a mid-term target to reduce the intensity of Scope 1 and Scope 2 GHG emissions by 20% by 2034, using 2024 as the base year. This strategy aligns with the 1.5°C temperature control target set in the Paris Agreement.
Innovation and Social Impact
Fosun's Health segment has achieved several breakthroughs, including HANSIZHUANG, the world's first monoclonal antibody targeting PD-1 approved for first-line treatment of extensive-stage small cell lung cancer. HLX22 became the world's first anti-HER2-targeted therapy to receive Orphan Drug Designation approvals from the U.S. FDA and the European Commission for gastric cancer. As of December 31, 2025, Fosun Pharma's independently developed artesunate for injection had saved more than 88 million severe malaria patients worldwide, with over 440 million doses supplied globally.
The Fosun Foundation, established in 2012, manages the company's social responsibility initiatives. The Rural Doctors Program, launched in 2017, has covered 78 counties in 16 provinces, supporting 25,000 rural doctors and benefiting 3 million rural families. In biodiversity conservation, the Sea Turtle Shelter at the Atlantis Sanya aquarium was inaugurated on May 23, 2026, covering 388 square meters to provide rehabilitation and habitat for rescued sea turtles.
How will Fosun allocate capital to achieve its 20% reduction in Scope 1 and Scope 2 GHG emissions by 2034?
What is the expected commercial impact of HANSIZHUANG and HLX22 on Fosun Pharma's revenue in the next fiscal year?
Will the MSCI AAA rating facilitate lower financing costs for Fosun's upcoming green bond issuances?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
